TED Ted Baker Plc

    14 December 2004

             Tepnel Life Sciences PLC (`Tepnel' or `the Company')              

                            Shareholding in Company                            

Manchester, UK. 14 December 2004 *The Company received notification on 13
December from Finsbury Worldwide Pharmaceutical Trust plc, that it has acquired
37,000,000 shares of 1p each in the Company ("Shares"). The shares were
acquired in the recent placing of 74,477,000 ordinary shares of the Company at
a price of 5.65 pence per share announced on 2 November 2004, and represent
approximately 17.38% of the Company's enlarged issued share capital.

Finsbury Worldwide Pharmaceutical Trust plc is also interested in warrants to
purchase 37,000,000 ordinary shares in the Company at 6.98 pence per share.

Finsbury Worldwide Pharmaceutical Trust plc is managed by OrbiMed Capital LLC.

For Further Information:

Tepnel Life Sciences plc
Ben Matzilevich, CEO

Gron Ffoulkes-Davies, Finance Director

0161 946 2200

Seymour Pierce

Mark Percy, Corporate Finance

0207 107 8000

De Facto Communications

Helena Podd

020 7940 1000

Notes to Editors

About Tepnel Life Sciences plc

Tepnel is a UK-based international life sciences instrumentation and services
company with a `tri-polar' strategy focused on providing the biomedical
industry with high-throughput automated DNA purification systems, manual DNA
purification kits and reagents, as well as scientific services for nucleic acid
purification, drug analysis, genotyping and genetically modified foods. Tepnel
was founded in 1992 to exploit DNA technology generated at UMIST (University of
Manchester Institute of Science and Technology) and is quoted on the AIM
segment of the London Stock Exchange (AIM: TED). More information on Tepnel can
be found at www.tepnel.com.



END

Ted Baker (LSE:TED)
Historical Stock Chart
From Jun 2024 to Jul 2024

Ted Baker (LSE:TED)
Historical Stock Chart
From Jul 2023 to Jul 2024